Imophoron

Imophoron

Imophoron is a Bristol, U.K.-based company developing a novel vaccine platform for use on emerging infectious diseases.

Imophoron is developing a novel vaccine platform for use on emerging infectious diseases. The platform is based on a single component of the human Adenovirus that spontaneously forms a superparticle, the ADDomer.

The team have demonstrated tumor clearance in a melanoma (skin cancer) mouse model and are now developing a universal vaccine candidate for viral diseases including Chikungunya, Dengue and Zika.

Technology

Imophoron's primary technology platform is ADDomer, an adenovirus-derived multimeric protein-based self-assembling nanoparticle scaffold engineered to facilitate plug-and-play display of multiple immunogenic epitopes from pathogens. The technology was developed at the University of Bristol in collaboration with other institutions.

The researchers used cryo–electron microscopy at near-atomic resolution and implemented novel, cost-effective, high-performance cloud computing to reveal architectural features of these self-assembling protein nanoparticles in unprecedented detail.

ADDomer technology forms the basis of Imophoron's vaccine development work. The first implementation of ADDomer in a vaccine candidate was targeted at the Chikungunya virus.

The resulting vaccines made using ADDomer are stable and require no refrigeration. The company is currently engaged in pre-clinical trials.

SARS-CoV-2 Vaccine Research

In April 2020, Imophoron partnered with University's COVID-19 Emergency Research Group (UNCOVER) to apply its ADDomer vaccine platform in the development of a vaccine for SARS-CoV-2, the virus which causes COVID-19.

Timeline

December 5, 2017
Imophoron was founded.

People

Name
Role
LinkedIn

Frederic Garzoni

Imre Berger

Further reading

Title
Author
Link
Type
Date

MultiBac IC-BEVS for Producing VLP-based Vaccines

Imre Berger

Presentation

2018

The Science Behind the Technology - Episode 1 - Imophoron's Vaccine Platform - Unit DX

Web

March 6, 2018

Documentaries, videos and podcasts

Title
Date
Link

ADDomer - A new kind of vaccine for untreatable infection

ADDomer: how big data can vaccinate the world

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.